May 7 |
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
|
May 2 |
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
|
Apr 30 |
Daré Bioscience secures $22 million in non-dilutive strategic royalty financing
|
Apr 30 |
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
|
Apr 23 |
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
|
Apr 11 |
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
|
Apr 1 |
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
|
Mar 29 |
Q4 2023 Dare Bioscience Inc Earnings Call
|
Mar 29 |
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Dare Bioscience GAAP EPS of -$0.35 beats by $0.02, revenue of $2.81M beats by $0.69M
|